Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DSM closes citric acid plant

This article was originally published in The Tan Sheet

Executive Summary

The Netherlands-based life and material sciences firm will close its Wuxi, China citric acid manufacturing plant by the first quarter of 2009, DSM announces Aug. 15. The closure comes after a request from the local government to relocate the plant because its current location is slated for urban development, DSM says. The firm does not expect to incur a loss due to the closing of the plant since the Wuxi government compensated DSM. The company decided not to rebuild the plant, but to relocate operations to its Tienen, Belgium site. ... Invests in Provexis: DSM Venturing acquires a 29.3 percent equity stake in Provexis, a development and licensing firm for functional food ingredients, medical foods and supplements. "The investment is in line with DSM's strategy to further expand in ingredients for functional food and dietary supplements focusing on, for example, cardiovascular and digestive health, two areas also addressed by Provexis," DSM says in an Aug. 27 release. Provexis' lead product is FruitFlow, a biotactive from tomato extract that improves blood flow for cardiovascular health, DSM says. Several large food manufacturers, including Unilever, have expressed interest in the ingredient, the firm says

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

Topics

UsernamePublicRestriction

Register

PS102048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel